Matthew Helmut Kulke MD
Chief, Section of Hematology and Medical Oncology, Boston University and Boston Medical Center
Join to view full profile
265 Western AveSte 2South Portland, ME 04106
Phone+1 207-661-0200
Fax+1 207-661-0299
Dr. Kulke is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Matthew H. Kulke, MD is the Chief of Hematology/Oncology at Boston Medical Center, Co-Director of the BU/BMC Cancer Center and the Zoltan Kohn Professor at Boston University Chobanian & Avedisian School of Medicine (Boston University Chobanian & Avedisian School of Medicine). He is internationally recognized for his expertise in neuroendocrine tumors and has led numerous national and international clinical trials resulting in new drugs and therapies for this indication. He is a past chair of the NCCN neuroendocrine tumor guidelines committee and the North American Neuroendocrine Tumor Society. Dr. Kulke has published more than 200 peer-reviewed articles in his area of expertise.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1997- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1995
University of California San Francisco School of MedicineClass of 1992
Princeton UniversityBA, Molecular Biology, Summa Cum Laude, 1983 - 1987
Certifications & Licensure
ME State Medical License 2025 - 2027
MA State Medical License 1995 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017
Clinical Trials
Publications & Presentations
PubMed
- Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogeny.Pratik Np Singh, Elsa Hadj Bachir, James R Howe, Andrew M Bellizzi, Paloma Cejas
The Journal of Clinical Investigation. 2026-07-01 - Phase II Trial of Cabozantinib in Combination with Nivolumab for Advanced Extrapancreatic Neuroendocrine Tumors.Kimberly J Perez, Nora Horick, Joanna Baginska, Anita Giobbie-Hurder, Ilana Gomez Diaz
Clinical Cancer Research. 2026-02-04 - Safety of immune checkpoint inhibitors in a diverse patient population: a single-institution experience.Grace M Ferri, John F Murphy, Akash Oza, Alexander J B Bulteel, Wafaa Abbasi
Ecancermedicalscience. 2026-01-01
Press Mentions
Boston Globe’s Rare Disease Summit Emphasizes the Importance of Community with the Treatment of Rare DiseasesMarch 22nd, 2025- TerSera® Announces Publication of Real-World Study on Xermelo® (Telotristat Ethyl) in Patients with Carcinoid Syndrome DiarrheaOctober 27th, 2021
- Boston Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital Formalize Cancer Clinical Trial CollaborationSeptember 29th, 2020
Grant Support
- Molecular And Genetic Analysis Of Neuroendocrine Tumor Risk And SurvivalNational Cancer Institute2011
- Molecular Analysis Of Esophageal Cancer SurvivalNational Cancer Institute2003–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
